Clément Martin, Cabana Jérôme, Holleran Brian J, Leduc Richard, Guillemette Gaétan, Lavigne Pierre, Escher Emanuel
Department of Pharmacology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada.
J Biol Chem. 2009 Sep 25;284(39):26603-12. doi: 10.1074/jbc.M109.012922. Epub 2009 Jul 27.
The octapeptide hormone angiotensin II (AngII) binds to and activates the human angiotensin II type 1 receptor (hAT(1)) of the G protein-coupled receptor class A family. Several activation mechanisms have been proposed for this family, but they have not yet been experimentally validated. We previously used the methionine proximity assay to show that 11 residues in transmembrane domain (TMD) III, VI, and VII of the hAT(1) receptor reside in close proximity to the C-terminal residue of AngII. With the exception of a single change in TMD VI, the same contacts are present on N111G-hAT(1), a constitutively active mutant; this N111G-hAT(1) is a model for the active form of the receptor. In this study, two series of 53 individual methionine mutations were constructed in TMD I, II, IV, and V on both receptor forms. The mutants were photolabeled with a neutral antagonist, (125)I-[Sar(1),p-benzoyl-L-Phe(8)]AngII, and the resulting complexes were digested with cyanogen bromide. Although no new contacts were found for the hAT(1) mutants, two were found in the constitutively active mutants, Phe-77 in TMD II and Asn-200 in TMD V. To our knowledge, this is the first time that a direct ligand contact with TMD II and TMD V has been reported. These contact point differences were used to identify the structural changes between the WT-hAT(1) and N111G-hAT(1) complexes through homology-based modeling and restrained molecular dynamics. The model generated revealed an important structural rearrangement of several TMDs from the basal to the activated form in the WT-hAT(1) receptor.
八肽激素血管紧张素II(AngII)与A类G蛋白偶联受体家族的人血管紧张素II 1型受体(hAT(1))结合并激活该受体。针对这个家族已经提出了几种激活机制,但尚未通过实验验证。我们之前使用甲硫氨酸邻近分析法表明,hAT(1)受体跨膜结构域(TMD)III、VI和VII中的11个残基与AngII的C末端残基紧密相邻。除了TMD VI中的一个单一变化外,组成型活性突变体N111G-hAT(1)上存在相同的接触;这种N111G-hAT(1)是受体活性形式的模型。在本研究中,在两种受体形式的TMD I、II、IV和V中构建了两个系列的53个单独的甲硫氨酸突变体。用中性拮抗剂(125)I-[Sar(1),p-苯甲酰-L-Phe(8)]AngII对突变体进行光标记,然后用溴化氰消化所得复合物。虽然在hAT(1)突变体中未发现新的接触点,但在组成型活性突变体中发现了两个,即TMD II中的苯丙氨酸-77和TMD V中的天冬酰胺-200。据我们所知,这是首次报道配体与TMD II和TMD V的直接接触。通过基于同源性的建模和受限分子动力学,利用这些接触点差异来识别野生型hAT(1)和N111G-hAT(1)复合物之间的结构变化。生成的模型揭示了野生型hAT(1)受体中几个TMD从基础形式到激活形式的重要结构重排。